Early diagnosis and surgical management of prostate cancer

Cancer Treatment Reviews

Volumn 29, Issue 3, 2003, Pages 151-160

  Linton, Kate D ^a   Hamdy, Freddie C ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGING; CANCER CENTER; CANCER LOCALIZATION; CANCER SCREENING; CANCER SURVIVAL; CLINICAL RESEARCH; DIAGNOSTIC TEST; EARLY DIAGNOSIS; EUROPE; HUMAN; LAPAROSCOPIC SURGERY; MALE; MORBIDITY; MORTALITY; PELVIS; POPULATION RESEARCH; POSTOPERATIVE COMPLICATION; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; REVIEW; STANDARDIZATION; SURGICAL ANATOMY; SURGICAL TECHNIQUE; TRANSRECTAL ULTRASONOGRAPHY; TREATMENT OUTCOME; TREATMENT PLANNING; UNITED STATES; UROLOGIC SURGERY;

EID: 0037805552     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-7372(03)00096-3     Document Type: Review

References (69)

1. Ahmedin J, Thomas A, Murray T, Thun M. CA Cancer J Clin 2002; 52(1): 23-47.
2. Jenson OM, Esteve J, Renard H. Cancer in the European Community and its member states. Eur J Cancer 1990; 26: 1167-1256.
3. Wilson JMG, Jungner G. Principles and practice of screening for disease. Geneva, World Health Organization, 1968. (Public health papers No. 34).
4. Bartsch G, Horninger W, Klocker H, Reissigl A, Oberaigner W, Schonitzer D, Severi G, Robertson C, Boyle P. Tyrol Prostate Cancer Screening Group: Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology 2001; 58: 417-424.
5. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJJ, Petros JA, Andriole GL. Measurement of prostate specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991; 324: 1156-1161.
6. Brawer MK, Cheli CD, Neaman IE, Goldblatt J, Smith C, Schawrtz MK, et al. Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer. J Urol 2000; 163: 1476-1480.
7. Recker F, Kwiatkowski MK, Piironen T, Petterson K, Huber A, Lummen G, et al. Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ confined cancer compared with prostatic specific antigen. Urology 2000; 55: 481-485.
8. Barry MJ. Clinical practice. Prostate-specific-antigen testing for early diagnosis of prostate cancer. N Engl J Med 2001; 344: 1373-1377.
9. Lilja H. Role of hK2, free PSA, and complexed PSA measurements in the very early detection of prostate cancer. Eur Urol 2001; 39(Suppl 4): 47-48.
10. Haggman MJ, Macoska JA, Wojno KJ, Oesterling JE. The relationship between prostatic intraepithelial neoplasia and prostate cancer: critical issues. J Urol 1997; 158: 12-22.
11. Wilkinson BA, Hamdy FC. State-of-the-art staging in prostate cancer. BJU Int 2001; 87(5): 423-430.
12. Schroder FH, van der Maas P, Beemsterboer P, Kruger AB, Hoedemaeker R, Rietbergen J, Kranse R. Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 1998; 90: 1817-1823.
13. Holmberg L, Bill-Axelson A, Helgesen F, Salo JO, Folmerz P, Haggman M, Andersson SO, Spangberg A, Busch C, Nordling S, Palmgren J, Adami HO, Johansson JE, Norlen BJ. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer; Scandinavian Prostatic Cancer Group Study Number 4. N Engl J Med 2002; 347: 781-789.
14. Steineck G, Helgesen F, Adolfsson J, Dickman PW, Johansson JE, Norlen BJ, Holmberg L. Quality of life after radical prostatectomy or watchful waiting. Scandinavian Prostatic Cancer Group Study Number 4. N Engl J Med 2002; 347: 790-796.
15. Begg CB, Riedel ER, Bach PB, Kattan MW, Schrag D, Warren JL, Scardino PT. Variations in morbidity after radical prostatectomy. N Engl J Med 2002; 346: 1138-1144.
16. Donovan J, Mills N, Smith M, Brindle L, Jacoby A, Peters T, Frankel S, Neal D, Hamdy F. Improving design and conduct of randomised trials by embedding them in qualitative research: ProtecT (prostate testing for cancer and treatment) study. BMJ 2002; 325: 766-770.
17. Barnes RW. Survival with conservative therapy. JAMA 1969; 210(2): 331.
18. Johansson JE, Adami HO, Andersson SO, Bergstrom R, Krusemo UB, Kraaz W. Natural history of prostate cancer: a population based study of 223 untreated patients. Lancet 1989; 1: 799-803.
19. Johansson JE, Holmberg L, Johansson S, Bergstrom R, Adami HO. Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA 1997; 277: 467-471.
20. Chodak GW, Thisted RA, Gerber GS, Johansson JE, Adolfsson J, Jones GW, Chisholm GD, Moskovitz B, Livne PM, Warner J. Results of conservative management of clinically localized prostate cancer. N Engl J Med 1994; 330: 242 248.
21. Albertsen PC, Frybeck DG, Storer BE, Kolon TF, Fine J. Long-term survival among men with conservatively treated localized prostate cancer. JAMA 1995; 274: 626-631.
22. Albertsen PC, Hanley JA, Gleason DF, Barry MJ. A competing risk analysis of men age 55-74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998; 280: 975-980.
23. Oliver SE, Gunnell D, Donovan JL. Comparison of trends in prostate-cancer mortality in England and Wales and the USA. Lancet 2000; 355: 1788-1789.
24. Lu-Yao G, Albertsen PC, Stanford JL, Stukel TA, Walker-Corkery ES, Barry MJ. Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. BMJ 2002; 325: 740.
25. Wilt TJ, Brawer MK. The prostate cancer intervention versus observation trial (PIVOT). Oncology (Huntingt) 1997; 11(8): 1133.
26. Partin AW, Yoo JK, Carter HB, Parson JD, Chan DW, Epstein JI, et al. The use of prostatic specific antigen, clinical stage and Gleason score to predict pathological stage in men with prostate cancer. J Urol 1993; 150: 110-114.
27. Carvalhal GF, Smith DS, Mager DE, Ramos C, Catalona WJ. Digital rectal examination for detecting prostate cancer at prostatic specific antigen levels of 4 ng/mL or less. J Urol 1999; 161: 835-839.
28. Nadji M, Tabei SZ, Castro A, Chu TM, Murphy GP, Wang MC, et al. Prostatic-specific antigen: an immunohistologic marker for prostatic neoplasms. Cancer 1981: 1229-1232.
29. Catalona WJ, Smith DS, Ratliff L, et al. Measurement of prostate specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991; 324: 1156-1161.
30. Christensson A, Bjork T, Nilsson O, et al. Serum prostate specific antigen complexed to α1-antichymotrypsin as an indicator of prostate cancer. J Urol 1993; 150: 100.
31. Luderer AA, Chen Y, Thiel R, et al. Measurement of the proportion of free to total PSA improves diagnostic performance of PSA in the diagnostic grey zone of total PSA. Urology 1995; 46: 187-194.
32. Catalona WJ, Partin AW, Slawin KM, et al. Use of percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicentre clinical trial. J Am Med Assoc 1998; 279: 1542-1547.
33. Catalona WJ, Southwick PC, Slawin KM, et al. Comparison of percent free PSA, PSA density, and age-specific PSA cut-offs for prostate cancer detection and staging. Urology 2000; 56: 255-260.
34. Benson MC, Whang IS, Olsson CA, et al. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol 1992; 147: 817-821.
35. Benson MC, Whang IS, Pantuck A, et al. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol 1992; 147: 815-816.
36. Djavan B, Zlotta AR, Byttebier G, et al. Prostate specific antigen density of the transition zone for early detection of prostate cancer. J Urol 1998; 160: 411-419.
37. Carter HB, Morrell CH, Pearson JD, et al. Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostatic disease. Cancer Res 1992; 52: 3323-3328.
38. Carter HB, Pearson JD, Metter J, et al. Longitudinal evaluation of prostate specific antigen levels in men with and without prostate disease. JAMA 1992; 267: 2215.
39. Pearson JD, Carter HB. Natural history of changes in prostate specific antigen in early stage prostate cancer. J Urol 1994; 152: 1743-1748.
40. Carter HB, Pearson JD, Chan DW, et al. Prostate specific antigen variability in men without prostate cancer: effect of sampling interval on prostate-specific antigen velocity. Urology 1995; 45: 591.
41. Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum prostate-specific antigen in the community-based population of healthy men: establishment of age-specific reference ranges. JAMA 1993; 270: 860-864.
42. Dalkin BL, Ahmann FR, Kopp JB. Prostate specific antigen levels in men older than 50 years without clinical evidence of prostate carcinoma. J Urol 1993; 150: 1837-1839.
43. Christensson A, Laurell C-B, Lilja H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 1990; 194: 755-763.
44. Catalona WJ, Smith DS, Wolfert R, Wang TJ, Rittenhouse H, Ratliff TL, Nadler RB. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 1995; 274: 1214-1220.
45. Arcangeli CG, Shepherd DL, Smith DS, et al. Correlation of percent free PSA with pathologic features of prostatic carcinomas. J Urol 1996; 155: 415.
46. Pannek J, Rittenhouse HG, Chan DW, Epstein JI, Walsh PC, Partin AW, et al. The use of percent free prostatic-specific antigen for staging of men with clinically localised prostate cancer. J Urol 1998; 159: 1238-1242.
47. Pannek J, Subong ENP, Jones KA, Marschke PL, Epstein JI, Chan DW, et al. The role of free/total prostatic-specific antigen ratio in the prediction of final pathological stage for men with clinically localised prostate cancer. Urology 1996; 48: 51-54.
48. Lerner SE, Jacobson SJ, Lilja H, Berg stralh EJ, Ransom J, Klee GG, et al. Free complexed and total serum prostate specific antigen concentrations and their proportions in predicting stage, grade, and deoxyribonucleic acid ploidy in patients with adenocarcinoma of the prostate. Urology 1996; 48: 224-240.
49. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6-4.0 ng/ml and benign prostate examination: enhancement of specificity with free PSA measurements. JAMA 1997; 277: 1452-1455.
50. Recker F, Kwiatkowski MK, Piironen T, Petterson K, Huber A, Lummen G, et al. Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ confined cancer compared with prostatic specific antigen. Urology 2000; 55: 481-485.
51. Haese A, Becker C, Noldus J, Graefen M, Huland E, Huland H, et al. Human glandular kallikrein 2: a potential serum marker for predicting the organ confined versus non-organ confined growth of prostate cancer. J Urol 2000; 163(May): 1491-1497.
52. Watanabe H, Kato H, Kato T, Masayoshi M. Diagnostic application of the ultrasonotomography for the prostate. Jpn J Urol 1968; 59: 273-279.
53. Lorentzen T, Nerstom H, Iverson P, Torp-Pederson ST. Local staging of prostate cancer with transrectal ultrasound: a literature review. Prostate Supp 1992; 4: 11-16.
54. Rifkin MD, Zerhouni EA, Gatsonis CA, Quint LE, Paushter DM, Epstein JI, et al. Comparison or magnetic resonance imaging and ultrasonography in staging early prostate cancer-results of a multi-institutional cooperative trial. N Engl J Med 1990; 323: 621-626.
55. Smith JA, Scardino PT, Resnick MI, Hernandez AD, Rose SC, Egger MJ, et al. Transrectal ultrasound versus digital rectal examination for the staging of carcinoma of the prostate: results of a prospective multi-institutional trial. J Urol 1997; 157: 902-906.
56. Hardeman SW, Causey JQ, Hickey DP, Soloway MS. Transrectal ultrasound for staging prior to radical prostatectomy. Urology 1989; 34: 175-180.
57. Liebross RH, Pollack A, Lankford SP, Zagars GK, von Eshenbach AC, Geara FB. Transrectal ultrasound for staging prostate carcinoma prior to radiation therapy. Cancer 1999; 85: 1577-1585.
58. Ukimura O, Troncoso P, Ramirez EI, Babaian RJ. Prostate cancer staging: correlation between ultrasound determined tumor contact length and pathologically confirmed extraprostatic extension. J Urol 1998; 159: 1251-1259.
59. Balaji KC, Fair WR, Feleppa EJ, et al. The role of advanced 2 and 3-dimensional ultrasound for detecting prostate cancer. J Urol 2002; 168: 2422-2425.
60. Rodriguez LV, Terris MK. Risks and complications of transrectal ultrasound guided prostate needle biopsy: a prospective study and review of the literature. J Urol 1998; 160: 2115-2120.
61. Young HH. The early diagnosis and radical cure of carcinoma of the prostate. Being a study of 40 cases and presentation of a radical operation, which was carried out in four cases. John Hopkins Hosp Bull 1905; 16: 315-321.
62. Millin T. Retropubic Urinary Surgery. Williams and Wilkins: Baltimore, MD, 1947.
63. Walsh PC, Donker PJ. Impotence following radical prostatectomy: insight into etiology and prevention. J Urol 1982; 128: 492-497.
64. Walsh PC, Lepor H, Eggleston JC. Radical prostatectomy with preservation of sexual function: anatomical and pathological considerations. Prostate 1983; 4: 473-485.
65. Myers RP. Prostate shape, external striated urethral sphincter, and radical prostatectomy: the apical dissection. J Urol 1987; 138: 543-550.
66. Catalona WJ, Ramos CG, Carvalhal GF. Contemporary results of anatomic radical prostatectomy. CA Cancer J Clin 1999; 49: 282-296.
67. Burkhard FC, Bader P, Schneider E, Markwalder R, Studer UE. Reliability of preoperative values to determine the need for lymphadenectomy in patients with prostate cancer and meticulous lymph node dissection. Eur Urol 2002; 42(2): 84-90, discussion 90-2.
68. Schuessler W, Kavoussi LR, Clayman R, et al. Laparoscopic radical prostatectomy: initial case report. J Urol 1992; 4: 246A.
69. Guillonneau B, Valancien G. Laparoscopic radical prostatectomy: the Montsouris experience. J Urol 2000; 163: 418-422.